Neurocrine Biosciences Gets Breakthrough Therapy Designation From FDA For Crinecerfont In Congenital Adrenal Hyperplasia
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences announced at its Analyst Day that it received FDA Breakthrough Therapy Designation for Crinecerfont in Congenital Adrenal Hyperplasia. The company also shared updates on its R&D portfolio, including plans to advance two gene therapies into the clinic by 2025 and expects to have at least 20 development candidates by 2027.
December 05, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences received FDA Breakthrough Therapy Designation for Crinecerfont, which could expedite its development and review process, potentially leading to faster market access and revenue generation.
The FDA Breakthrough Therapy Designation is a positive regulatory milestone that can lead to increased investor confidence and a potential uptick in the stock price due to the prospects of accelerated development and approval process. This designation often results in increased attention from investors and can be seen as a validation of the drug's potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100